Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4639964
Max Phase: Preclinical
Molecular Formula: C35H45FN4O12
Molecular Weight: 732.76
Molecule Type: Unknown
Associated Items:
ID: ALA4639964
Max Phase: Preclinical
Molecular Formula: C35H45FN4O12
Molecular Weight: 732.76
Molecule Type: Unknown
Associated Items:
Canonical SMILES: COC[C@@H]1[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](NC(=O)c2cn(C3CC3)c3c(OC)c(N4CCN(C)CC4)c(F)cc3c2=O)[C@H](OC(C)=O)[C@H]1OC(C)=O
Standard InChI: InChI=1S/C35H45FN4O12/c1-17(41)49-30-24(16-47-6)31(50-18(2)42)33(52-20(4)44)26(32(30)51-19(3)43)37-35(46)23-15-40(21-8-9-21)27-22(29(23)45)14-25(36)28(34(27)48-7)39-12-10-38(5)11-13-39/h14-15,21,24,26,30-33H,8-13,16H2,1-7H3,(H,37,46)/t24-,26-,30-,31-,32-,33+/m0/s1
Standard InChI Key: MXOXOAGVKOHKBJ-WIWAWKAYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 732.76 | Molecular Weight (Monoisotopic): 732.3018 | AlogP: 1.34 | #Rotatable Bonds: 11 |
Polar Surface Area: 181.24 | Molecular Species: NEUTRAL | HBA: 15 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.34 | CX Basic pKa: 6.06 | CX LogP: 0.33 | CX LogD: 0.31 |
Aromatic Rings: 2 | Heavy Atoms: 52 | QED Weighted: 0.26 | Np Likeness Score: -0.10 |
1. Suaifan GARY, Mohammed AAM.. (2019) Fluoroquinolones structural and medicinal developments (2013-2018): Where are we now?, 27 (14): [PMID:31182257] [10.1016/j.bmc.2019.05.038] |
Source(1):